Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Cardiff Oncology, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO, DEC. 08, 2025 (GLOBE NEWSWIRE) -- CARDIFF ONCOLOGY, INC. (NASDAQ: CRDF), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEVERAGING PLK1 INHIBITION TO DEVELOP NOVEL THERAPIES ACROSS A RANGE OF CANCERS, TODAY ANNOUNCED THAT CLINICAL DATA FROM AN INVESTIGATOR-SPONSORED TRIAL WITH ONVANSERTIB IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) WILL BE PRESENTED IN A POSTER PRESENTATION AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING.

CARDIFF ONCOLOGY ANNOUNCES CLINICAL DATA FROM INVESTIGATOR-SPONSORED TRIAL WITH ONVANSERTIB IN CHRONIC MYELOMONOCYTIC LEUKEMIA AT ASH 2025

SAN DIEGO, DEC. 08, 2025 (GLOBE NEWSWIRE) -- CARDIFF ONCOLOGY, INC. (NASDAQ: CRDF), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEVERAGING PLK1 INHIBITION TO DEVELOP NOVEL THERAPIES ACROSS A RANGE OF CANCERS, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PRESENT AND HOST ONE-ON-ONE MEETINGS AT SIDOTI'S YEAR-END VIRTUAL INVESTOR CONFERENCE, WHICH IS TAKING PLACE FROM DECEMBER 10-11, 2025.

CARDIFF ONCOLOGY TO PRESENT AT SIDOTI'S YEAR-END VIRTUAL INVESTOR CONFERENCE

SAN DIEGO, NOV. 24, 2025 (GLOBE NEWSWIRE) -- CARDIFF ONCOLOGY, INC. (NASDAQ: CRDF), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEVERAGING PLK1 INHIBITION TO DEVELOP NOVEL THERAPIES ACROSS A RANGE OF CANCERS, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AND 1X1 INVESTOR MEETINGS AT THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE, WHICH IS TAKING PLACE FROM DECEMBER 2-4, 2025.

CARDIFF ONCOLOGY TO PRESENT AT THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE

 ANNOUNCED POSITIVE DATA FROM THE ONGOING PHASE 2 CRDF-004 TRIAL EVALUATING ONVANSERTIB + STANDARD OF CARE FOR THE TREATMENT OF FIRST-LINE RAS-MUTATED METASTATIC COLORECTAL CANCER   EXPECTS TO REPORT AN UPDATE FROM THE PHASE 2 CRDF-004 TRIAL IN Q1 2026   CASH AND INVESTMENTS OF $60.6 MILLION AS OF SEPTEMBER 30, 2025, PROJECTED RUNWAY INTO Q1 2027  SAN DIEGO, NOV. 06, 2025 (GLOBE NEWSWIRE) -- CARDIFF ONCOLOGY, INC. (NASDAQ: CRDF), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEVERAGING PLK1 INHIBITION TO DEVELOP NOVEL THERAPIES ACROSS A RANGE OF CANCERS, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A BUSINESS UPDATE. THIS QUARTER WAS MARKED BY HIGHLY ENCOURAGING DATA FROM OUR ONGOING CRDF-004 TRIAL EVALUATING ONVANSERTIB IN COMBINATION WITH STANDARD OF CARE FOR FIRST-LINE RAS-MUTATED MCRC.

CARDIFF ONCOLOGY REPORTS THIRD QUARTER 2025 RESULTS AND PROVIDES BUSINESS UPDATE

SAN DIEGO, NOV. 04, 2025 (GLOBE NEWSWIRE) -- CARDIFF ONCOLOGY, INC. (NASDAQ: CRDF), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEVERAGING PLK1 INHIBITION TO DEVELOP NOVEL THERAPIES ACROSS A RANGE OF CANCERS, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES IN NOVEMBER 2025.

CARDIFF ONCOLOGY TO PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES

SAN DIEGO, OCT. 02, 2025 (GLOBE NEWSWIRE) -- CARDIFF ONCOLOGY, INC. (NASDAQ: CRDF), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEVERAGING PLK1 INHIBITION TO DEVELOP NOVEL THERAPIES ACROSS A RANGE OF CANCERS, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES IN OCTOBER 2025.

 TRIAL DEMONSTRATES 49% CONFIRMED ORR IN THE 30MG ONVANSERTIB DOSE ARM VERSUS 30% CONFIRMED ORR IN THE CONTROL ARM IN INTENT-TO-TREAT POPULATION (N=110) 

CARDIFF ONCOLOGY ANNOUNCES POSITIVE DATA FROM ONGOING RANDOMIZED PHASE 2 FIRST-LINE RAS-MUTATED MCRC CLINICAL TRIAL (CRDF-004)

 VETERAN EXECUTIVE WITH OVER 20 YEARS OF ONCOLOGY LEADERSHIP AND CLINICAL EXPERIENCE WITH PROVEN TRACK RECORD OF SUCCESS IN BRINGING DEVELOPMENT CANDIDATES THROUGH LATE-STAGE CLINICAL DEVELOPMENT

CARDIFF ONCOLOGY APPOINTS DR. ROGER SIDHU AS CHIEF MEDICAL OFFICER AND ANNOUNCES TIMING FOR THE NEXT UPDATE FROM THE CRDF-004 TRIAL IN FIRST-LINE RAS-MUTATED MCRC

 RESULTS FROM PHASE 1B CLINICAL TRIAL EVALUATING ONVANSERTIB + PACLITAXEL FOR METASTATIC TRIPLE NEGATIVE BREAST CANCER DEMONSTRATED 40% OBJECTIVE RESPONSE RATE 

CARDIFF ONCOLOGY ANNOUNCES POSITIVE DATA FROM INVESTIGATOR-INITIATED TRIAL OF ONVANSERTIB IN COMBINATION WITH PACLITAXEL IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER PRESENTED AT ASCO 2025

- COMPLETED ENROLLMENT IN RANDOMIZED PHASE 2 CRDF-004 TRIAL EVALUATING ONVANSERTIB + STANDARD OF CARE FOR THE TREATMENT OF FIRST-LINE RAS-MUTATED METASTATIC COLORECTAL CANCER (MCRC) - - EXPANDED INTELLECTUAL PROPERTY PORTFOLIO WITH SECOND PATENT COVERING TREATMENT OF ALL BEV-NAVE PATIENTS, INCLUDING RAS-MUTATED AND RAS WILD-TYPE MCRC, ACROSS ALL LINES OF THERAPY - - CASH AND INVESTMENTS OF $79.9 MILLION AS OF MARCH 31, 2025, PROJECTED RUNWAY INTO Q1 2027 - SAN DIEGO, MAY 08, 2025 (GLOBE NEWSWIRE) -- CARDIFF ONCOLOGY, INC. (NASDAQ: CRDF), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEVERAGING PLK1 INHIBITION TO DEVELOP NOVEL THERAPIES ACROSS A RANGE OF CANCERS, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND PROVIDED A BUSINESS UPDATE. OUR LEAD PROGRAM FOR ONVANSERTIB HAS REMAINED ON TRACK IN 2025 WITH THE SUCCESSFUL COMPLETION OF ENROLLMENT IN OUR TRIAL IN FIRST-LINE RAS-MUTATED MCRC, UNDERSCORING OUR DEEP COMMITMENT TO SERVING A PATIENT POPULATION THAT HAS SEEN NO THERAPEUTIC ADVANCEMENTS IN DECADES, SAID MARK ERLANDER, CHIEF EXECUTIVE OFFICER OF CARDIFF ONCOLOGY.

Cardiff Oncology, Inc.

CRDF

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Cardiff Oncology, Inc.

CRDF.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CRDF